Kewaunee Scientific (KEQU) AGM 2026 summary

Opening remarks and agenda

• Meeting convened virtually to enhance access and participation for stockholders, associates, and directors.

• Chairman introduced board members and outlined the meeting's three-part structure: formal business, CEO review, and Q&A.

• The meeting agenda included a review of fiscal year 2026, business investments, strategic direction, and a Q&A session.

Board and executive committee updates

• Three Class I directors—Thomas D. Hull III, David S. Rhind, and John D. Russell—were nominated and re-elected for three-year terms expiring in 2029.

• Board composition and classified structure reaffirmed, with staggered terms for directors.

• Two new leaders joined the Lab Products Group to drive international growth and operational alignment.

Overview of voting outcomes

• Quorum established with 87.8% of shares represented.

• All nominated directors re-elected by plurality vote.

• Ratification of Forvis Mazars, LLP as independent auditors for fiscal year 2027 approved.

• Advisory approval of named executive officer compensation for fiscal year 2026 passed.